54 related articles for article (PubMed ID: 9869161)
1. A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B.
Igrutinović Z; Hooimeijer HL; Kentouche K; Botha J; Turecek PL; Kokot-Kierepa M; Gazda HT
J Blood Med; 2024; 15():113-122. PubMed ID: 38481741
[TBL] [Abstract][Full Text] [Related]
2. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
Fukutake K; Togo K; Xu L; Markson LE; Alvir JMJ; Winburn I; Karumori T
J Blood Med; 2023; 14():649-661. PubMed ID: 38143791
[TBL] [Abstract][Full Text] [Related]
3. Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors.
Shu M; Malcolmson C; Bosch A; Markovic T; Wakefield C; Bouskill V; Carcao M
Haemophilia; 2024 Jun; ():. PubMed ID: 38924261
[TBL] [Abstract][Full Text] [Related]
4. Extravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding.
Leuci A; Enjolras N; Marano M; Daniel M; Brevet M; Connes P; Dargaud Y
J Thromb Haemost; 2024 Mar; 22(3):700-708. PubMed ID: 38072379
[TBL] [Abstract][Full Text] [Related]
5. Two-Step Size-Exclusion Nanofiltration of Prothrombin Complex Concentrate Using Nanocellulose-Based Filter Paper.
Manukyan L; Mantas A; Razumikhin M; Katalevsky A; Golubev E; Mihranyan A
Biomedicines; 2020 Mar; 8(4):. PubMed ID: 32224972
[TBL] [Abstract][Full Text] [Related]
6. Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.
Monroe DM; Jenny RJ; Van Cott KE; Buhay S; Saward LL
Adv Hematol; 2016; 2016():7678901. PubMed ID: 26997955
[TBL] [Abstract][Full Text] [Related]
7. Is the strategy to fix healthcare in shared value?
Pantelidis O
Aust Health Rev; 2024 Apr; 48():113-115. PubMed ID: 38573781
[No Abstract] [Full Text] [Related]
8. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.
Yu JK; Iorio A; Edginton AN;
Res Pract Thromb Haemost; 2019 Jul; 3(3):528-541. PubMed ID: 31294337
[TBL] [Abstract][Full Text] [Related]
9. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
Iorio A; Edginton AN; Blanchette V; Blatny J; Boban A; Cnossen M; Collins P; Croteau SE; Fischer K; Hart DP; Ito S; Korth-Bradley J; Lethagen S; Lillicrap D; Makris M; Mathôt R; Morfini M; Neufeld EJ; Spears J
Res Pract Thromb Haemost; 2018 Jul; 2(3):535-548. PubMed ID: 30046759
[TBL] [Abstract][Full Text] [Related]
10. Using pharmacokinetics to individualize hemophilia therapy.
Iorio A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):595-604. PubMed ID: 29222309
[TBL] [Abstract][Full Text] [Related]
11. The History of Clotting Factor Concentrates Pharmacokinetics.
Morfini M
J Clin Med; 2017 Mar; 6(3):. PubMed ID: 28335525
[TBL] [Abstract][Full Text] [Related]
12. Individualized factor IX dosing in two brothers: application of longitudinal pharmacokinetic modelling to optimize therapeutic benefit.
Brown JT; Wicklund BM; Abdel-Rahman SM
Haemophilia; 2015 Mar; 21(2):e125-e127. PubMed ID: 25420419
[No Abstract] [Full Text] [Related]
13. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.
Björkman S; Ahlén V
Eur J Clin Pharmacol; 2012 Jun; 68(6):969-77. PubMed ID: 22281721
[TBL] [Abstract][Full Text] [Related]
14. Secondary prophylaxis with factor IX concentrates: continuous infusion.
Morfini M
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Björkman S; Berntorp E
Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
[TBL] [Abstract][Full Text] [Related]
16. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
